65 yaş üstü erişkinlerde aşı uygulamaları

Öz

Koruyucu sağlık hizmetleri; bağışıklama, ilaçla korunma, erken tanı, yeterli ve dengeli beslenme, aile planlaması ve sağlık eğitimi olarak alt gruplara ayrılmaktadır. Bağışıklama, bulaşıcı hastalıklara karşı kişileri korumanın en etkili ve ucuz yollarından birisidir. Aşıya ihtiyaç çocukluk çağı ile birlikte sona ermemektedir. Aksine erişkinleri pek çok hastalıktan, komplikasyonlarından ve ölümden korumaktadır. 65 yaş ve üzeri kişilerde enfeksiyon hastalıklarına yatkınlık artmaktadır. Türkiye’de 65 yaş üzerinde uygulanması önerilen aşılar mevsimsel influenza, pnomokok, herpes zoster ve tetanoz aşılarıdır. Dünya genelinde ve Türkiye’de çocukluk aşılamalarına benzer bir algoritmanın yaşlılar için de hızla planlanıp uygulanmasına ihtiyaç bulunmaktadır.

Anahtar Kelimeler

• aşı
• enfeksiyon hastalıkları
• yaşlı.

Vaccination applications in adults over 65 years of age

Öz

Preventive health services; immunization, drug prevention, early diagnosis, adequate and balanced nutrition, family planning and health education. Immunization is one of the most effective and inexpensive ways to protect people against infectious diseases. The need for vaccination does not end with childhood. On the contrary, it protects adults from many diseases, complications and death. People aged 65 and over are more prone to infectious diseases. Vaccines recommended to be administered over the age of 65 in Turkey are seasonal influenza, pneumococcal, herpes zoster and tetanus vaccines. There is a need for an algorithm similar to childhood vaccinations to be quickly planned and implemented for the elderly in the world and in Turkey.

Anahtar Kelimeler

• adult
• infectious diseases
• vaccination

Kaynakça

1. 1. Öztek Z. Yaşlılara verilen sağlık hizmetleri. In: Yeşim GK, eds. Basic Geriatrics. Ankara: Güneş Medical Bookstores;2007:125-140.
2. 2. Şenol E. Yaşlanma ve immünoloji. In: Yeşim GK, eds. Basic Geriatrics. Ankara: Güneş Medical Bookstores;2007:689-94.
3. 3. Turkey Infectious Diseases and Clinical Microbiology Specialist Association. Adult immunization guide. Erişim: https://www. ekmud.org.tr/haber/264-turkiye-ekmud-eriskin-bagisiklama-rehberi. Erişim tarihi: 14.03.2022.
4. 4. Dişcigil G. Yaşlılık döneminde koruyucu sağlık bakımı. In: Tufan İ, Durak M, eds. Gerontoloji Bakım ve Sağlık II. Cilt. Ankara: Nobel Medical Bookstores;2018:520-21.
5. 5. World Health Organisation. Global health estimates. Erişim:https://www.who.int/data/ global-health-estimates. Erişim tarihi: 13.03.2022.
6. 6. T.C. Sağlık Bakanlığı. COVID-19 Bilgilendirme Platformu. Erişim: https://covid19.saglik.gov.tr/. Erişim tarihi: 04.04.2022.
7. 7. Hamborsk J, Kroger A, Wolfe S. Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington: Public Health Foundation; 2017
8. 8. Ferdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine. 2021;39(28):3678-3695. doi: 10.1016/j.vaccine.2021.05.011.

9. 9. Hall E, Wodi AP, Hamborsky J. Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington: Public Health Foundation; 2021.
10. 10. Centers For Disease Control and Prevention (C.D.C.). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Adults aged≥ 65 years. Erişim: https://www.cdc.gov/vaccines/acip/recs/GRADE/pneumo-vac-adult.pdf. Erişim tarihi: 03.04.2022.
11. 11. Kobayashi M, Farrar JL, Gierke R. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States. MMWR Morb Mortal Wkly Rep 2022;71:109–117.
12. 12. Centers For Disease Control and Prevention (C.D.C.). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): recombinant zoster vaccine (RZV) and herpes zoster live attenuated vaccine (ZVL). Erişim: https://www.cdc.gov/vaccines/acip/recs/grade/herpes-zoster.html#. Erişim tarihi: 07.04.2022.
13. 13. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine. 2016: 375(11);1019-1032.
14. 14. T.C. Sağlık Bakanlığı. COVID-19 Bilgilendirme Platformu. Erişim: https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html. Erişim tarihi: 21.04.2022.
15. 15. World Health Organisation. The Sinovac Covid 19 Vaccine What You Need To Know. Erişim: https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know. Erişim tarihi: 01.05.2022.
16. 16. World Health Organisation. One hundred million cases in one hundred weeks Working towards better COVID-19 outcomes in the WHO European Region. Erişim: https://apps.who.int/iris/bitstream/handle/10665/352368/WHO-EURO-2022-4888-44651-63377-eng.pdf?sequence=1&isAllowed=y. Erişim tarihi:01.05.2022.
17. 17. Wikipedia. Pfizer BioNTech COVID-19. Erişim: https://tr.wikipedia.org/wiki/Pfizer-BioNTech_COVID-19_a%C5%9F%C4%B1s%C4%B1. Erişim tarihi: 05.05.2022.
18. 18. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022:376;e069761.
19. 19. Tenforde MW, Self WH, Gaglani M. Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022; 71:459–465.
20. 20. Sütlü S, Til A. Immunization status and factors affecting individuals aged 65 years and above with chronic diseases who are registered wıth family physicians in Burdur province. Turkish Journal of Geriatrics, 2021; 24(41): 71-78. doi : 10.31086/tjgeri.2021.201